Alleima AB (publ) - Deep Dive Research Report

Ticker: ALLEI.ST (Nasdaq Stockholm) | Sector: Basic Materials (Specialty Steel & Alloys) Report date: 2026-06-09 | Most recent reporting period: Q1 2026 (reported 27 April 2026) Currency: Swedish krona (SEK) throughout

Section 1: What the Company Does

Alleima makes the metal that goes where ordinary metal fails. When a customer needs a tube, a wire, a strip of steel, or a heating element that has to survive seawater two kilometres under the ocean, the inside of a nuclear steam generator, the acid bath of a chemical reactor, or the 1,800-degree interior of an industrial furnace, they call a company like Alleima. The product is not commodity stainless steel sold by the tonne. It is highly engineered alloy, sold by the metre or the kilogram, where the value is in the metallurgy and the manufacturing precision, not the weight of the steel.

Put plainly: Alleima is an advanced materials company that melts its own special alloys from raw metal and converts them into three families of finished products - seamless tubes, electric heating elements and resistance wire, and precision strip steel. It is one of very few companies in the world that controls the entire chain from the melt (its own steelworks) all the way to a finished, certified, ultra-thin tube or wire. That vertical integration, from melting recipe to finished surface, is the heart of why a customer cannot easily switch away.

The founding story matters here because it explains both the technical depth and the recent corporate structure. The business traces to 1862, when Göran Fredrik Göransson founded Sandvikens Jernverk in Sweden and became one of the first industrialists in the world to make the Bessemer steelmaking process work at commercial scale. For 160 years this materials business lived inside the larger Sandvik group as "Sandvik Materials Technology." In 2019 the Sandvik board decided to separate it, and on 31 August 2022 it was spun off, renamed Alleima, and listed on Nasdaq Stockholm at an initial valuation of roughly SEK 10 billion. The name "Alleima" is a constructed word, but the business is one of the oldest continuously operating specialty-steel operations on earth. CEO Göran Björkman rang the opening bell.

The core value proposition is corrosion resistance, high-temperature performance, and reliability in applications where failure is catastrophic or extremely expensive. An offshore umbilical tube that springs a leak can shut in an entire subsea oilfield. A steam generator tube that cracks can take a nuclear reactor offline for months. A razor blade steel that does not hold its edge ruins a billion-unit consumer product. Alleima's pitch is that its alloys and its manufacturing tolerances are good enough that the customer never has to think about the metal.

The technical nature is what makes this hard to replicate. Alleima does not buy steel and shape it. It formulates its own grades, including proprietary super-duplex and hyper-duplex stainless steels, nickel alloys, titanium, and zirconium, melts them in its own facilities, and then draws, rolls, and finishes them down to tolerances measured in microns. A medical guidewire, an umbilical tube, and a razor-blade strip all start as a metallurgical recipe and end as a certified product that has passed qualification testing that can take years. Building that capability took over a century and cannot be bought off a shelf.

A concrete example: a subsea oil-and-gas developer building a deepwater field needs umbilical tubing - the slender steel "veins" bundled inside an umbilical cable that carries hydraulic fluid and chemicals from the surface platform down to the wellheads on the seabed. The tubing must resist seawater corrosion and enormous pressure for the 20-to-30-year life of the field, with zero tolerance for leaks. Alleima has supplied more than 160 million metres of umbilical tubing to all major umbilical fabricators across every offshore region. It melts a super-duplex grade, draws it into long continuous lengths, tests every metre, and ships it to a cable fabricator who bundles it. If that tube fails, the field stops producing. That is why the customer pays a premium and does not shop on price.

Section 2: Business Segments

Alleima runs three operating divisions: Tube, Kanthal, and Strip. They share a metallurgical heritage but serve genuinely different customers with different economics, which is why they are managed separately.

Tube Division (≈70% of group revenue)

Tube is the company. In 2025 it generated SEK 13,063 million of revenue (roughly 70% of the group's SEK 18,630 million), at an adjusted EBIT margin of 8.9%, with about 4,555 full-time employees under division president Carl von Schantz.

What it does: Tube makes seamless tubes and other long products in advanced stainless steels and special alloys. The flagship product families are umbilical tubes for offshore oil and gas; heat-exchanger tubes for chemical, petrochemical and power plants; OCTG (oil country tubular goods, the tubing that lines oil and gas wells); steam-generator tubes for nuclear reactors; and medical tubes for trauma, dental, surgical, cardiovascular and diagnostic devices. End markets are Industrial, Chemical and Petrochemical, Oil and Gas, Mining and Construction, Power Generation (including Nuclear), and Transportation. Geographically the division skews to Europe (49% of revenue), then North America (22%) and Asia (21%).

The core capability: Alleima controls the full chain from its own melt to the finished tube, which lets it guarantee both the alloy chemistry and the dimensional precision. In umbilicals it is the global leader, having shipped over 160 million metres. In nuclear it has delivered tube bundles to more than 400 steam generators in over 20 countries and has produced over 60 million metres of nuclear fuel tubing for more than 100 reactors over fifty-plus years. That installed base is a moat: a nuclear utility qualifies a steam-generator-tube supplier through a process that can take a decade, and once qualified, it does not casually re-shop.

Why it stands alone: Tube is capital-intensive, project-driven, and long-cycle. Its customers place large, lumpy orders with long delivery horizons (nuclear visibility can run years), which is a fundamentally different rhythm from Kanthal's heating elements or Strip's high-volume consumer steel. The 60-year-old expansion press it replaced in 2025 tells you how long-lived this asset base is.

Competitive position: Main competitors are Nippon Steel (Japan), Tubacex (Spain), Salzgitter Mannesmann (Germany), Jiuli (China), and Haynes International (US, now part of Acerinox). Alleima wins on the most demanding grades, umbilicals, and nuclear; it loses, or chooses not to compete, on lower-spec, price-driven tube where Asian producers dominate.

Role in the group: This is the scale engine and the source of the company's long-cycle backlog, but its margin (8.9%) is structurally below Kanthal's. It is where the cyclical oil-and-gas and chemical exposure sits, and where the 2025 weakness concentrated.

Kanthal Division (≈21% of group revenue)

Kanthal is the quality engine. In 2025 it generated SEK 3,996 million of revenue (about 21% of group), at an adjusted EBIT margin of 16.4% - nearly double Tube's - with about 1,472 employees.

What it does: Kanthal makes industrial heating technology and resistance materials. Its core products are electric heating elements (described as the widest range on the market, operating from 50°C to 1,850°C across different atmospheres), resistance heating materials and wire used to build heating elements and thermocouples, ultra-fine wire in stainless steel and precious metals for medical devices and electronics, and furnace tubes and diffusion cassettes for semiconductor and industrial processes. End markets are Industrial Heating, Consumer, Medical, and increasingly Electronics/Semiconductors. Geographically Kanthal leans to North America (37%), then Europe (30%) and Asia (26%).

The core capability: Kanthal's resistance-alloy metallurgy (the Kanthal brand is over a century old and is effectively a category name in electric heating) plus its precision-wire drawing for medical applications. Medical wire goes into devices implanted in or operated inside the human body, so the qualification and traceability requirements are extreme and the margins reflect it.

Why it stands alone: Kanthal's economics, customers, and demand drivers are different. It is shorter-cycle, higher-margin, less capital-intensive, and exposed to two structural growth themes - the electrification of industrial heat (replacing gas-fired furnaces with electric ones to cut carbon) and medical-device growth - rather than the oil-and-gas capex cycle. It also carries the Kanthal brand, a genuine standalone identity.

Competitive position: Competitors include Aperam, VDM Metals (Acerinox-owned), and Tokai in heating/resistance materials, and Fort Wayne Metals and Heraeus specifically in medical wire. Kanthal competes on the breadth of its element range and its high-temperature alloy know-how.

Role in the group: This is the margin engine and the cleanest growth story, anchored on Medical (consistently strong through 2025-26) and the multi-year electrification/decarbonization thesis in Industrial Heating.

Strip Division (≈8% of group revenue)

Strip is the smallest and the most operationally troubled. In 2025 it generated SEK 1,571 million (about 8% of group), at an adjusted EBIT margin of just 3.9%, with about 525 employees under president Per Eklund.

What it does: Strip makes ultra-thin precision strip steel: knife, razor, and doctor-blade steel; compressor valve steel for refrigerator and air-conditioner compressors; and coated strip for fuel-cell bipolar plates. End markets are Consumer (white goods, razor blades), Medical, Industrial, and Transportation. It is heavily Asia-weighted (46% of revenue), then Europe (41%).

The core capability: Rolling steel to extreme thinness and surface quality with very close tolerances. Razor-blade steel, for instance, is slit to finished size with cemented-carbide tools to achieve edge quality good enough for a product made in the billions.

Why it stands alone: Strip is high-volume, consumer-cycle-driven, and structurally lower-margin than the other two. It also houses the company's fuel-cell coated-strip bet (the "Sandvik/Sanddikken" coated-strip line referenced on calls), an emerging clean-energy option that has so far been a drag.

Competitive position: Competitors are Proterial (Japan, formerly Hitachi Metals), Voestalpine (Austria), Jindal (India), and Zapp (Germany). Strip wins on the high end (compressor valve steel, razor steel) but has been hurt by weak fuel-cell volumes and production-efficiency problems.

Role in the group: The smallest division and currently the problem child. Order intake has actually grown fastest (Strip booked +24-30% organic order growth through 2025), but operationally it has under-delivered, posting negative or low-single-digit EBIT margins and inventory write-downs during 2025.

Segment summary

Section 3: Products and Business Detail

Alleima groups its catalogue into roughly eight product families that map onto the three divisions.

Tube and pipe (Tube division). This is the broadest catalogue. It includes umbilical tubes in super-duplex and hyper-duplex steel for subsea oil and gas (Alleima's global leadership product, 160m+ metres supplied); heat-exchanger tubes in austenitic stainless, duplex, nickel alloys, titanium and zirconium for chemical plants, refineries and power stations; OCTG production tubing for oil and gas wells; steam-generator tubes for nuclear reactors (400+ steam generators served, with capacity now being expanded ~60% via a SEK 330 million investment, explicitly to serve both full-scale plants and the emerging Small Modular Reactor market); boiler and superheater tubes for power generation; and medical tubes for trauma, dental, surgical, cardiovascular and diagnostic devices. The certifications matter enormously - nuclear and aerospace tube require qualification regimes that take years and lock in incumbents.

Furnace products and resistance materials (Kanthal division). Electric heating elements spanning 50-1,850°C; resistance wire and ribbon (the Kanthal-brand alloys used to build heating elements industry-wide); thermocouple and temperature-sensing materials; furnace tubes and diffusion cassettes for semiconductor wafer processing. Kanthal also makes ultra-fine medical and electronic wire in stainless and precious metals.

Strip steel and coated strip (Strip division). Knife, razor and doctor-blade steel; compressor valve steel for white-goods compressors; precision strip for springs and medical; and coated strip for fuel-cell bipolar plates and hydrogen electrolysers - the clean-energy option line.

Wire-based solutions and bar. Across divisions, Alleima also supplies medical wire and components, solid and hollow bar (including nickel-alloy bar and rock-drill steel), fittings and flanges, and billets and blooms used as forging and extrusion feedstock.

Manufacturing footprint and process. The defining feature is vertical integration: Alleima operates its own steelmaking (melting and casting its proprietary alloy grades) and then converts in-house through hot and cold working, drawing, rolling, heat treatment, and finishing. Core production is anchored in Sweden (the historic Sandviken works), with downstream and specialty operations across Europe, North America, and Asia. The melt-to-finished-product control is the source of both its quality guarantee and its capital intensity.

Recent capacity milestones that change the business:

• A new production line at the Zhenjiang, China mill, finalized in 2025, strengthening high-quality tube for chemical and petrochemical customers in Asia (Q4 2025 report).
• A Penang, Malaysia expansion for the Medical segment and nuclear steam-generator tubes, with deliveries expected by end of 2026 (Q4 2025 call).
• A ~60% capacity increase in steam-generator tubing (SEK 330 million), targeting both conventional nuclear and Small Modular Reactors.
• Replacement of a 60-plus-year-old expansion press in the Tube division during the 2025 summer maintenance shutdown, improving automation and productivity (Q2-Q3 2025 calls).

Section 4: Customers

Alleima sells across ten primary industries: chemical and petrochemical, consumer, industrial, industrial heating, hydrogen and renewable energy, medical, mining and construction, nuclear, oil and gas, and transportation. The buying relationship differs sharply by segment.

Who buys, and who decides. In Tube, the buyers are project engineers and procurement teams at umbilical fabricators (for subsea), EPC contractors and oil-and-gas operators (for OCTG), chemical-plant and refinery operators (heat exchangers), and nuclear utilities and reactor builders (steam-generator tubes). The decision-maker is rarely a pure purchasing agent buying on price - it is an engineering qualification authority who has to certify that the material meets a specification. In Kanthal Medical, the buyer is a device manufacturer's R&D and supply-chain function. In Strip, the buyer is a high-volume manufacturer (a razor-blade maker, a compressor manufacturer, a white-goods OEM).

Why they choose Alleima. The reasons are specific: proprietary alloy grades that competitors cannot exactly match; melt-to-finish control that guarantees chemistry and tolerance; a track record in failure-critical applications (160m metres of umbilical, 400+ nuclear steam generators); and certifications already held. For a nuclear or aerospace customer, the fact that Alleima is already qualified is itself the reason.

Switching costs. These are high in Tube and Kanthal Medical and low in commodity Strip. In nuclear, switching a steam-generator-tube supplier means re-qualifying a new vendor through a multi-year regulatory and engineering process - prohibitive unless the incumbent fails. In medical, a device that has been approved with a specific wire or tube supplier would need re-validation, and potentially regulatory re-filing, to change. In umbilicals, the field's design is built around a qualified tube. By contrast, razor-blade and compressor-valve steel face more substitutable competition.

Concentration. The business is diversified across ten end markets and three divisions, which management repeatedly frames as its defining strength. On the Q3 2025 call the CEO said the company is "clearly benefiting from a diversified exposure," and on the Q2 2025 call he framed it as "our broad exposure reduces volatility." This diversification is real: in 2025, Tube weakness in oil and gas and chemical was partly offset by Kanthal medical strength and Strip order growth. No single customer dominates the disclosed picture.

Contract structure. The mix runs from long-cycle, high-visibility backlog (nuclear, large umbilical projects, OCTG) to shorter-cycle book-and-ship business (Kanthal industrial heating, Strip consumer). Management distinguishes its "solid backlog in key segments such as oil and gas, nuclear and medical" - which gives near-term delivery visibility - from "short-cycle business," which is where the 2025-26 demand weakness and order postponements concentrated. The long-cycle backlog is what cushions revenue when short-cycle orders soften.

Section 5: Competitive Landscape

The specialty stainless and special-alloy tube/wire/strip industry is not a commodity steel market and is not a single market. Alleima competes against different sets of companies in each division, and the structure of competition differs by product.

In high-end seamless tube (umbilicals, nuclear, demanding heat exchangers), the field is narrow: a handful of integrated specialty producers globally can melt the alloys and hold the tolerances. Alleima is one of the leaders, particularly in umbilicals and nuclear steam-generator tubes, where its installed base and qualifications create durable incumbency. In commodity and mid-spec tube, Asian producers (Chinese mills like Jiuli, plus Japanese and Korean integrated steelmakers) compete hard on price, and Alleima largely does not chase that volume. In electric heating and resistance materials, the Kanthal brand competes against a small set of specialist alloy houses. In precision strip, competition is broader and more price-exposed.

Why Alleima wins or loses. It wins where metallurgy and qualification dominate the buying decision - umbilicals, nuclear, medical wire and tube, high-temperature heating. It is exposed where the product is more substitutable or where Asian cost producers set the price (commodity tube, some consumer strip). Barriers to entry in its core are high: a century-plus of alloy know-how, in-house melting, multi-year customer qualifications, and reference installed bases that a new entrant cannot replicate. Barriers in commodity strip and mid-spec tube are far lower.

Structural shifts. Consolidation has reshaped the peer set: Acerinox acquired both VDM Metals and Haynes International, pulling two former independent specialty-alloy competitors into one group. Chinese specialty-tube capacity continues to expand. And tariffs/trade rules (US and EU) became a live competitive variable in 2025-26, with management stating it can largely compensate for tariff costs through pricing and footprint.

Market caps are approximate, in the listing currency, as of June 2026, and move continuously; they are shown only as a peer-size reference.

Section 6: Industry

What drives demand. Alleima sits at the intersection of several distinct demand engines because it serves ten end markets. The biggest are: oil-and-gas capex (umbilicals and OCTG track offshore and onshore drilling investment); chemical and petrochemical plant construction and maintenance (heat-exchanger tube); nuclear new-build and life-extension (steam-generator and fuel tube), now boosted by the small-modular-reactor wave; medical-device growth (tube and wire), a structural grower tied to ageing populations and procedure volumes; the electrification of industrial heat (Kanthal heating elements replacing gas furnaces to decarbonize); and consumer durables (razor blades, white-goods compressors via Strip). Hydrogen and fuel cells are an emerging, currently small and volatile, driver.

Industry size and trajectory. Alleima operates in the specialty/precision segment of stainless and special-alloy steel, not the bulk stainless market. The global precision stainless steel tube market is tracked by multiple market-research houses as a multi-billion-dollar niche growing at low-to-mid single digits, with the high-alloy, failure-critical sub-segments (nuclear, subsea, medical) growing faster than commodity tube. The relevant structural tailwinds - nuclear revival (including SMRs), industrial-heat electrification, and medical-device growth - are multi-year and largely policy- and demographics-driven rather than purely cyclical.

Position in the supply chain. Alleima is upstream of the device or plant builder but downstream of raw metal. It buys nickel, chromium, molybdenum, titanium and other inputs, melts its own grades, and ships finished tube/wire/strip to fabricators, OEMs, and EPC contractors. Because it melts in-house, it carries metal-price exposure (the calls repeatedly quantify "metal price effects" of SEK 50-150 million per quarter) and currency exposure (a Sweden-heavy cost base selling globally, with FX swings of SEK 90-290 million hitting quarterly EBIT in 2025-26).

Regulation. Certification is a defining industry feature and a barrier. Nuclear tube requires regulatory and utility qualification; medical tube and wire feed into device approvals (FDA, CE/MDR); aerospace and oil-and-gas grades carry their own qualification regimes. These approvals protect incumbents and slow new entry. Trade policy - US and EU tariffs on steel - became materially relevant in 2025-26, both as a cost and as a competitive lever.

Cyclicality. The business is genuinely cyclical but diversified. Tube's oil-and-gas, chemical, and short-cycle industrial demand swings with the capex cycle and was the main drag in 2025-26 as customers postponed investment amid geopolitical and tariff uncertainty. Nuclear and medical are far more stable and counter-cyclical, and Strip's consumer demand follows a different rhythm again. The net effect, as management stresses, is that diversification dampens but does not eliminate the cycle.

Tailwinds vs headwinds. Tailwinds: nuclear revival and SMRs, industrial-heat electrification, medical growth, and reshoring/tariff-driven Western capacity preference. Headwinds: weak European and North American short-cycle industrial demand, chemical and petrochemical softness, customer investment postponement under geopolitical uncertainty, and volatile hydrogen/fuel-cell demand.

Section 7: Growth Triggers

Drawn directly from the five most recent concalls. Forward-looking items only.

• Steam-generator-tube capacity expansion (~+60%) for nuclear, including SMRs. A SEK 330 million investment to lift SGT capacity by roughly 60%, targeting both full-scale plants and the emerging Small Modular Reactor market. Nuclear was repeatedly flagged as high-activity with a long, visible backlog. (Q3 2025 call, Oct 22 2025; reiterated Q4 2025 call, Jan 27 2026.)

  "High activity, growing demand, continue to support a solid backlog, providing good visibility going forward." (Q3 2025)

• Penang, Malaysia expansion for Medical and nuclear steam-generator tubes, deliveries by end of 2026. New capacity dedicated to two of the company's strongest segments. (Q4 2025 call, Jan 27 2026.)

• Zhenjiang, China new tube production line, finalized 2025. Strengthens high-quality tube for chemical and petrochemical customers in Asia, the market most exposed to local competition. (Q4 2025 report, Jan 27 2026.)

• Industrial-heat electrification ramp in Kanthal. Management pointed to improving industrial-heating demand, particularly electronics and semiconductors in Asia, and rising customer demand for electric heating solutions as a decarbonization play. By Q1 2026 this had turned into "good organic order growth" in Kanthal's Medical and Industrial Heating segments. (Q4 2025 call, Jan 27 2026; Q1 2026 call, Apr 27 2026.)

  "Demand within the Kanthal division was positive... particularly in the Medical and Industrial Heating segments, driven by customers' increasing demand for electric heating solutions." (Q1 2026)

• Pilot-scale electric process-gas heater via partner Danieli for a DRI plant in Abu Dhabi. Commercialization of Alleima's patented ProTal heating technology, compatible with hydrogen and natural gas, for direct-reduced-iron steelmaking - a new application for the electrification thesis. (Q2 2025 call, Jul 18 2025.)

• Tube expansion press replacement improving automation and productivity, recovery expected by mid-2026. The 60-year-old press replaced during 2025 maintenance is expected to lift Tube productivity, with the disruption reversing into a productivity benefit by mid-2026. (Q2 2025 call, Jul 18 2025; Q3 2025 call, Oct 22 2025.)

  "We will have a negative impact also in the fourth quarter [but expect partial recovery by mid-2026]." (Q3 2025)

• Cost-reduction program delivering ~SEK 200 million annual savings. Roughly 250 FTE reduction at a one-off cost of about SEK 400 million, with ~75% of savings permanent - a margin tailwind landing through 2026. (Q3 2025 call, Oct 22 2025.)

• Medical segment momentum across Tube and Kanthal, plus MDOX integration. Medical was the single most consistently positive theme across all five calls, with a successfully integrated acquisition (MDOX) and multiple growth drivers. (Q2-Q4 2025 and Q1 2026 calls.)

Section 8: Key Risks

Customer investment postponement in short-cycle business. The clearest and currently most active risk. Through 2025 and into 2026, geopolitical and tariff uncertainty caused customers in oil and gas, chemical, and short-cycle industrial to delay orders. Order intake on a rolling-12-month basis fell from positive organic growth in Q1 2025 to -12% organic in Q1 2026 (down 19% to SEK 16,266 million). This is high-probability and already happening; the question is duration. Management was blunt about the mechanism on the Q2 2025 call.

"When there is high tariffs... quite a number of customers speculate that it will go down. If they don't need steel at this certain moment, they wait with their purchase." (Q2 2025)

Currency exposure. With a Sweden-heavy cost base and global sales, FX swings hit reported EBIT hard - SEK -93 million in Q1 2026, ~290 basis points of margin headwind in Q4 2025, and guided SEK -240 million for Q1 2026. Hedging covers only part. This is a high-probability, moderate, recurring drag that can mask underlying operating performance.

Strip division operational underperformance. Strip booked strong order growth (+24-30% organic through 2025) but posted negative-to-low EBIT margins (a -4.2% adjusted EBIT margin in Q3 2025, 2.4% in Q2 2025) due to production-efficiency problems, poor mix, fuel-cell weakness, and inventory write-downs. The CEO admitted on Q2 2025: "The underlying strip performance is not in line with expectations." This is a real, company-specific execution risk - a division growing the top line while destroying margin.

Tube long-cycle backlog conversion risk. Tube depends on large, lumpy projects (OCTG, nuclear, umbilicals). Management flagged on the Q4 2025 call that "the OCTG backlog situation poses potential year-end risks if order booking doesn't accelerate." If big projects do not convert to firm orders, the scale engine stalls.

Metal-price volatility. Because Alleima melts its own alloys, nickel/chromium/moly price swings flow through (SEK 50-150 million per-quarter metal-price effects on the calls). Usually passed through over time but a timing risk to margins.

Hydrogen/fuel-cell demand volatility. The Strip coated-strip and Kanthal hydrogen-heater bets are early-stage and lumpy; management described hydrogen and renewable energy as a "headwind" in Q3 2025. Low near-term materiality but a risk to the clean-energy growth narrative.

Cyclical concentration in Tube. With ~70% of revenue in the most cyclical division, a deep or prolonged oil-and-gas/chemical capex downturn would hurt disproportionately, only partly cushioned by nuclear and medical.

Section 9: Walk the Talk

Five concalls reviewed, oldest to newest:

1. Q1 2025 - 23 April 2025 (CEO Göran Björkman, CFO Olof Bengtsson)
2. Q2 2025 - 18 July 2025 (CFO Olof Bengtsson)
3. Q3 2025 - 22 October 2025 (CFO Johan Eriksson)
4. Q4/FY 2025 - 27 January 2026 (CFO Johan Eriksson)
5. Q1 2026 - 27 April 2026 (CEO Björkman, CFO Johan Blomdahl Eriksson)

The most recent (27 April 2026) is within 90 days of today. Note a CFO transition during 2025: Olof Bengtsson handed over to Johan Blomdahl Eriksson, who is now CFO.

The arc of the story. In Q1 2025, Alleima looked like it was turning a corner. Revenue grew 8% organically to SEK 5,150 million, the adjusted EBIT margin expanded to 10.5%, rolling-12-month order intake turned positive (+1% organic) on the back of nuclear (Tube) and medical (Kanthal) strength, and management said "many parts of our business showed a positive development." That was the high-water mark.

From there, the message turned steadily more cautious - and management's caution proved well-calibrated rather than rosy. By Q2 2025 the CEO was already warning that customers were "hesitating taking investment decisions" and explicitly explaining the tariff-driven order-postponement dynamic. He did not pretend the weakness was temporary noise. Revenue declined 4% organically and the stock fell ~11% on the print, but the commentary was candid: he flagged that Q3 would carry summer-maintenance under-absorption "a little bit less than 100 basis points," currency headwinds of ~SEK 150 million, and that Strip was underperforming. All three came true.

On the Strip problem specifically, management has been refreshingly honest rather than evasive. In Q2 2025 the CEO said plainly, "The underlying strip performance is not in line with expectations," and named the causes (production efficiency, poor mix, inventory write-downs). He did not bury it. By Q3 2025 Strip was still negative (-4.2% EBIT margin), so the promised "improvement during the second half" did not materialize on schedule - a missed near-term commitment, openly visible in the numbers. That is the clearest example of a guided improvement slipping.

On costs, the Q3 2025 commitment to a ~SEK 200 million annual savings program at a ~SEK 400 million one-off cost was specific and quantified (≈250 FTE, ~75% permanent). This is the kind of concrete, trackable promise that will be judged through 2026; it was stated with unusual precision rather than vague "efficiency" language.

On capex discipline, management guided full-year 2025 capex of SEK 1.2 billion repeatedly (Q2, Q3) and landed at SEK 1.1 billion - delivered, slightly under. On the Tube press replacement, they guided in Q2-Q3 2025 that it would hurt through Q4 2025 with recovery by mid-2026; the Q4 2025 and Q1 2026 prints showed Tube remaining the weak division, consistent with that guidance. On dividends, the board has raised the payout every year since listing (see Section 10), matching a stated commitment to a progressive dividend.

The Q1 2026 result validated the cautious tone: revenue fell 11% (organic -5%), order intake worsened to -12% organic, and FX knocked SEK 93 million off EBIT - all roughly in line with the deteriorating trajectory management had been signaling for three quarters. Crucially, the diversification thesis they kept repeating actually worked: Kanthal (medical, electric heating) was positive even as Tube (oil and gas, chemical) was weak.

Assessment: This is a management team that does broadly what it says and, more importantly, does not sugar-coat. They flagged the demand slowdown early and openly, named their own Strip execution problem in plain language, and guided conservatively into deteriorating markets rather than promising a quick turn. The one clear miss - Strip's delayed margin recovery - was disclosed transparently as it happened, not hidden. The pattern reads as consistently candid and modestly conservative, not promotional. The main thing they have not yet delivered is the Strip turnaround.

Section 10: Shareholder Friendliness Index

Dividends. Alleima has raised its dividend every year since its 2022 listing. Dividend per share was SEK 2.00 for 2023, SEK 2.30 for 2024, and a proposed SEK 2.50 for 2025 (announced with the Q4 2025 report, a 9% increase), representing about a 71% payout of adjusted earnings. The trajectory is a steady, progressive rise even as 2025 earnings declined - a deliberate signal of confidence and a commitment to a progressive dividend policy. The ~71% payout ratio is on the higher side but not alarming; it reflects management choosing to hold the dividend trajectory through a cyclical down-year rather than cut.

Buybacks and dilution. MoatMap records zero buybacks in the trailing ~90 days (since 11 March 2026), and the broader public record shows Alleima has not run a share-repurchase program over its three-year public life - its capital-return policy is dividend-led, with retained capital funding organic capex (the Penang, Zhenjiang, and steam-generator-tube expansions) rather than buybacks. Shares outstanding are approximately 250 million (consistent with the 550,000-share insider purchase representing 0.22% of the company) and have stayed essentially flat since listing; there is no meaningful buyback retiring shares and no material option-driven dilution creating them. Net change in share count over three years is approximately flat.

Verdict: Returns Capital (dividend-led). Alleima returns cash through a steadily rising dividend that it held on its upward path through a down-year, while reinvesting the rest into capacity; it does not buy back stock.

Section 11: Insider Activities

Sweden's primary source is the Finansinspektionen (FI) insider register at marknadssok.fi.se, under EU MAR Article 19 PDMR rules. The MoatMap database (market: NORDIC) is the spine below; it sources from FI filings. I cross-checked the most recent fortnight and found no additional material filings beyond what MoatMap captured.

The headline event is a large open-market board purchase in February 2026.

(All sourced via Finansinspektionen insider register / MoatMap NORDIC, dates as shown.)

Buys - read the signal. The Claes Boustedt purchase is a very bullish signal. On 4 February 2026, board director Claes Boustedt bought 550,000 shares for roughly SEK 45.7 million in a single open-market transaction at about SEK 83.10. This is not a token, fee-converted board purchase - it is a large, deliberate, multi-tens-of-millions purchase representing about 0.22% of the entire company. Boustedt is closely tied to the Lundberg sphere (he is a long-standing executive in the L E Lundbergföretagen group, a major long-term Swedish industrial owner), so this is a conviction buy from an insider connected to one of the company's anchor-owner camps, made right as the order-intake cycle was deteriorating. An insider buying into weakness, at scale, is the strongest signal in this section. Very bullish signal.

The May 2026 transactions are routine, not signal. The cluster of "Other" transactions on 6-7 May 2026 - by the CEO, CFO, and three senior managers, all at the same ~SEK 83.62 price - are consistent with shares received or acquired under the company's incentive/long-term share program (matching/allocation), not discretionary open-market conviction buys. They are mildly positive (management is accumulating, not selling) but should not be over-read.

Sells. There were no insider sells in the trailing twelve months in the record. That absence is itself mildly positive - no director or officer chose to lighten into the share-price weakness.

Net assessment. Insiders are net buyers, and the activity is dominated by one large, high-conviction open-market purchase by a board member with anchor-owner ties, made during a cyclical order-intake downturn, with no offsetting sells. The remaining activity is benign incentive-program accumulation by the CEO, CFO and senior team. Concentration in one name (Boustedt) is the only caveat to calling it broad-based, but the direction is unambiguous. Read: bullish signal.

Section 12: Scenarios

Bull case. The cyclical order trough of 2025-26 proves to be the bottom, and the structural growth engines do the heavy lifting. Nuclear demand keeps building - the expanded steam-generator-tube capacity (and the SMR option) converts a deep, visible backlog into years of high-margin Tube revenue, while the Penang line comes online on schedule at end-2026 to serve both nuclear and a still-growing medical book. Kanthal's electrification thesis turns from "tentative" to real as industrial customers commit capex to electric heating, and the semiconductor/electronics recovery in Asia lifts furnace-product demand. The Strip turnaround finally lands - production efficiency normalizes, the fuel-cell drag fades, and the division's strong order growth (which was always there) drops through to margin. The cost program's SEK 200 million of savings sticks, currency stops fighting against the company, and the diversification that cushioned the downturn now amplifies the upturn. Management's candid, conservative reputation means that when they finally guide up, the market believes them. Insider conviction (the Boustedt buy) looks prescient.

Base case. The world looks much as it does today: a slow, uneven recovery. Tube stays soft in oil-and-gas and chemical short-cycle business while nuclear and medical hold up, so group revenue grinds rather than rebounds. Kanthal remains the margin anchor with steady medical growth and gradually improving industrial heating. Strip muddles - better than its 2025 low but not yet a strong contributor. The capacity investments (Zhenjiang, Penang, SGT expansion) come online and provide optionality without immediately transforming the numbers. Margins recover modestly as the cost program bites and FX headwinds eventually normalize. The dividend keeps rising on its progressive path. Management delivers roughly what it has signaled - measured improvement, no fireworks - and the diversification story continues to do exactly what they say it does: dampen the swings in both directions.

Bear case. The capex postponement that started in 2025 deepens into a genuine downturn. A prolonged oil-and-gas and chemical capex retrenchment hits the 70%-of-revenue Tube division hard, the OCTG backlog the company flagged as a year-end risk fails to convert, and the long-cycle nuclear/medical cushion is not large enough to offset a shrinking short-cycle book. Strip's operational problems prove structural rather than transitory - the fuel-cell bet keeps bleeding and precision-strip efficiency never recovers, turning a small division into a persistent margin sink. Tariffs and trade fragmentation force costly footprint changes and squeeze the Asian tube business just as the new Zhenjiang line ramps into a weak market. Currency stays an unrelenting headwind against a Sweden-heavy cost base. The 71% dividend payout, maintained through the down-year, starts to look stretched against falling earnings, raising the uncomfortable question of whether the progressive dividend can survive another weak year. The diversification that management leans on dampens the fall but cannot prevent it.

Sources: Alleima Q1 2026 interim report (Cision), Alleima Q1 2026 presentation PDF, Alleima Q1 2026 earnings call (Seeking Alpha), Alleima Q4 & full-year 2025 report, Q4 2025 earnings highlights (Yahoo), Alleima Q3 2025 earnings call (Investing.com), Alleima Q2 2025 earnings call (Investing.com), Alleima Q1 2025 interim report, Tube division, Kanthal division, Strip division, Alleima products, Alleima listed on Nasdaq Stockholm (Sandvik), Sandvik to Alleima history (Quartr), Nuclear steam generator tubes, Umbilical tubes, Claes Boustedt board profile, insider data via Finansinspektionen / MoatMap NORDIC.

Note: Section 13 (Further Reading) is omitted - SemiAnalysis, Stratechery, and MBI Deep Dives have no coverage of Alleima (all three focus on technology/semiconductors and equity software names; a search returned no Alleima articles).

A few things to flag on data integrity: I have all five required concalls (Q1 2025 through Q1 2026), with the latest (27 April 2026) inside the 90-day window. Two transcript fetches (Q2 2025 via a third-party aggregator) returned garbled executive names ("Joergmann/Beintzon"), which I corrected to the verified names (CEO Göran Björkman; CFOs Olof Bengtsson then Johan Blomdahl Eriksson) - the substantive commentary was intact. The Boustedt buy and dividend figures are cross-checked against primary Alleima/FI sources.